Mérieux Equity Partners backs Addmedica

The GP intends to accelerate the company's geographical expansion and develop its portfolio of speciality products for the treatment of rare diseases and pathologies.

The GP invested via its Mérieux Participations 3 fund, which held a first close on €200m in Q2 2018 and has a €300m target. The fund backs small- to mid-cap companies in western Europe and North America in health-related businesses, interested in nutrition sector and food safety. The fund typically invests €20-40m per company. 

Company
Founded in 2005 and based in Paris, Addmedica specialises in the development and marketing of medicinal products and medical devices for rare and debilitating diseases, including a treatment for sickle cell disease.

People
Mérieux Equity Partners – Jean-François Billet (senior partner); Quentin De Labarre (investment manager).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France